Published in J Clin Oncol on October 07, 2013
A statistical evaluation of dose expansion cohorts in phase I clinical trials. J Natl Cancer Inst (2015) 1.54
Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol (2014) 1.33
Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol (2015) 0.98
Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed? J Clin Oncol (2015) 0.98
Sequential monitoring of Phase I dose expansion cohorts. Stat Med (2016) 0.83
Dose expansion cohorts in Phase I trials. Stat Biopharm Res (2016) 0.83
Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials (2016) 0.75
Use of expansion cohorts in phase 1 trials and probability of success in phase 2 for 381 anticancer drugs. Clin Cancer Res (2017) 0.75
Evaluating the role of phase I expansion cohorts in oncologic drug development. Invest New Drugs (2016) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
Some practical improvements in the continual reassessment method for phase I studies. Stat Med (1995) 3.43
Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res (2009) 2.63
Dose-finding designs for HIV studies. Biometrics (2001) 2.22
Continual reassessment method for partial ordering. Biometrics (2011) 2.11
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008) 2.06
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
A new dose-finding design for bivariate outcomes. Biometrics (2003) 1.40
Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer (2006) 1.31
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27
A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26
Dose-escalation models for combination phase I trials in oncology. Eur J Cancer (2010) 1.13
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials (2010) 1.10
A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Stat Med (2006) 1.07
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2012) 1.06
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs (2012) 1.03
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res (2011) 1.03
A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemp Clin Trials (2005) 1.02
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin Trials (2012) 1.01
Continual Reassessment and Related Dose-Finding Designs. Stat Sci (2010) 1.00
Continual reassessment method with multiple toxicity constraints. Biostatistics (2010) 1.00
Extended model-based designs for more complex dose-finding studies. Stat Med (2011) 0.96
Incorporating lower grade toxicity information into dose finding designs. Clin Trials (2011) 0.96
Retrospective analysis of sequential dose-finding designs. Biometrics (2005) 0.95
Estimating the probability of toxicity at the target dose following an up-and-down design. Stat Med (2003) 0.91
Estimating the dose-toxicity curve in completed phase I studies. Stat Med (2011) 0.90
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol (2012) 0.89
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer (2012) 0.81
Continual reassessment method for partial ordering. Biometrics (2011) 2.11
Dose-finding design for multi-drug combinations. Clin Trials (2011) 1.63
Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics (2007) 1.32
Interplay of priors and skeletons in two-stage continual reassessment method. Stat Med (2012) 1.07
Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Stat Med (2014) 1.06
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol (2003) 0.98
Performance of two-stage continual reassessment method relative to an optimal benchmark. Clin Trials (2013) 0.97
Incorporating lower grade toxicity information into dose finding designs. Clin Trials (2011) 0.96
Sensitivity of dose-finding studies to observation errors. Contemp Clin Trials (2009) 0.96
Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med (2012) 0.95
Optimal designs for estimating the most successful dose. Stat Med (2006) 0.94
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res (2012) 0.94
Continual reassessment and related designs in dose-finding studies. Stat Med (2011) 0.93
Joint analysis of multi-level repeated measures data and survival: an application to the end stage renal disease (ESRD) data. Stat Med (2008) 0.93
Identifying the most successful dose (MSD) in dose-finding studies in cancer. Pharm Stat (2006) 0.92
Dose-escalation designs in oncology: ADEPT and the CRM. Stat Med (2008) 0.88
Penalized likelihood estimation for semiparametric mixed models, with application to alcohol treatment research. Stat Med (2012) 0.86
Phase I design for completely or partially ordered treatment schedules. Stat Med (2013) 0.86
Trajectory analyses in alcohol treatment research. Alcohol Clin Exp Res (2012) 0.83
Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection. Stat Med (2007) 0.80
Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 0.78
An approach to meta-analysis of dose-finding studies. Stat Med (2011) 0.76
Obtaining the optimal dose in alcohol dependence studies. Front Psychiatry (2012) 0.76
Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples. Stat Med (2003) 0.75